JUL 10, 2020 8:29 AM PDT

Injection 66% Better than Daily Pill to Prevent HIV

WRITTEN BY: Annie Lennon

Pharmaceutical company ViiV Healthcare has announced that its long-lasting, injectable drug, cabotegravir, is more effective than Truvada, Gilead Sciences' daily oral tablets, at preventing HIV. 

Until now, Truvada has been seen as the frontline measure after condoms to prevent HIV. With the results from the most recent trial, however, this may change. 

The results come from a randomized, multi-center, double-blind Phase IIb/III clinical trial. Participants included 4, 566 men and transgender women who have sex with men and were HIV-negative at the beginning of the study.

Among the 52 participants who acquired HIV throughout the trial, 13 were in the study group who received cabotegravir alongside placebo daily oral tablets, and 39 were in the group receiving daily oral Truvada with placebo injections. 

Thus, while 1.22% of those in the Truvada group acquired HIV, just 0.41% of those in the cabotegravir group acquired the virus. As such, the researchers concluded that the injection, given once every two months, was 66% more effective at preventing HIV than Truvada. 

"These data are truly ground-breaking, demonstrating that long-acting injectable cabotegravir dosed every two months is superior to daily oral FTC/TDF at preventing HIV in at-risk men and transgender women who have sex with men." says Kimberly Smith, head of research and development at ViiV Healthcare Research. 

"This advancement has the potential to be a game-changer for HIV prevention, offering an option with very high rates of effectiveness and the convenience of reduced dosing from daily to just six times per year."

While nausea was more common among those taking FTC/TDF during the trial, the most common side effects for those on cabotegravir were injection site reactions, hypertension, and fever. 

Cabotegravir is now being assessed for safety and efficacy for HIV prevention in over 3,000 sexually active women in several African countries. 

 

Sources: Clinical Trials ArenaNational Institutes of Health

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
JUN 18, 2020
Drug Discovery & Development
Gilead to Trial COVID-19 Drug on Children
JUN 18, 2020
Gilead to Trial COVID-19 Drug on Children
Following the emergency use authorization given to Remdesivir on May 1, Gilead Sciences has announced that it will condu ...
JUN 10, 2020
Drug Discovery & Development
Does Your Gut Microbiota Alter Drug Activity?
JUN 10, 2020
Does Your Gut Microbiota Alter Drug Activity?
Scientists have created a systematic way to evaluate how the microbial community in our gut influences drug behavior. Fi ...
JUL 20, 2020
Neuroscience
Phantom-Limb Pain Reduced by Brain-Computer Interface
JUL 20, 2020
Phantom-Limb Pain Reduced by Brain-Computer Interface
Phantom-limb pain is a condition in which amputees feel like their amputated limb is still attached to their bodies. Whi ...
JUL 30, 2020
Immunology
Gene Silencing Therapy Stops the Itch of Psoriasis
JUL 30, 2020
Gene Silencing Therapy Stops the Itch of Psoriasis
A team of Harvard researchers has identified a promising new approach for treating psoriasis — a topical lotion co ...
JUL 14, 2020
Drug Discovery & Development
Less Addictive Opioid
JUL 14, 2020
Less Addictive Opioid
Opioids continue to have a bad name, and for a good reason, the number of lives they took due to their abuse has led to ...
JUL 29, 2020
Drug Discovery & Development
Will We Have a COVID-19 Vaccine by Year-End?
JUL 29, 2020
Will We Have a COVID-19 Vaccine by Year-End?
This week, pharmaceutical companies Moderna and Pfizer launched giant Phase III 30,000-subject trials for their COVID-19 ...
Loading Comments...